We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RELX:NYSERELX PLC PLC Analysis

Data as of 2026-04-28 - not real-time

$36.39

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

RELX trades at $36.39, comfortably above its 20‑day SMA ($34.85) and 50‑day SMA ($33.92) but still below the 200‑day SMA ($41.50), indicating a short‑term bounce within a longer‑term downtrend. Technical momentum is bullish with the MACD line ($0.80) above its signal ($0.61) and a histogram of $0.19, while the RSI of 62 suggests the stock is approaching overbought territory. Fundamentally, the company posts a robust operating margin of 31% and a profit margin of 21%, with a PE of 24 versus an industry average of 31, signaling relative value, yet its price‑to‑book ratio of 83 and debt‑to‑equity of 304% highlight a capital‑intensive balance sheet. The dividend yield of 2.53% and a payout ratio of 57% are supported by strong free cash flow ($2.16 B) and operating cash flow ($2.84 B), suggesting sustainability. Analysts have upgraded Citi’s outlook to Buy and set a median price target of $52.45, implying a 44% upside, while the DCF fair value of $13.28 appears overly conservative. Market sentiment is extremely bullish (Fear‑Greed Index 89), but the 30‑day volatility of 24% and a historic max drawdown of –50% underscore downside risk. The stock’s low beta (~0.23) reduces systematic risk, and volume remains stable, supporting liquidity. Overall, the blend of strong cash generation, attractive valuation multiples relative to peers, and a supportive dividend makes RELX a compelling candidate for medium‑term investors, though the high leverage and near‑term technical overbought signals advise caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD with line above signal
  • RSI near overbought at 62
  • Support level at $32.13 and stable volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Target price $52.45 implies 44% upside
  • PE 24 vs industry 31 indicates relative discount
  • Strong margins and sustainable 2.53% dividend

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent free cash flow supporting dividend
  • High ROE (70%) despite leverage
  • Diversified global exposure reducing geographic risk

Key Metrics & Analysis

Financial Health

Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio24.1
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio83.0
Op. Cash Flow$2.8B
Free Cash Flow$2.2B
Industry P/E31.1

Technical Analysis

TrendNeutral
RSI62.6
Support$32.13
Resistance$37.78
MA 20$34.85
MA 50$33.92
MA 200$41.50
MACDBullish
VolumeStable
Fear & Greed Index89.25

Valuation

Fair Value$13.28
Target Price$52.45
Upside/Downside44.13%
GradeUndervalued
TypeValue
Dividend Yield2.53%

Risk Assessment

Beta0.42
Volatility24.06%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.